Company intelligence / Profile preview

Tamarisk Technologies Group

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

Tamarisk Technologies Group developed a novel oral drug delivery platform, SSNe, and demonstrated proof-of-concept with oral insulin and other compounds previously limited to IV administration; moving toward pre-clinical stage and clinical trials as of 2014-2015

Therapeutic areas: EndocrinologyOther
Modalities: Small moleculePeptideProteinPegylated peptideOral insulinNano-encapsulation-based oral drug delivery
Industry: Biotech

Partnerships

Engineered Biopharmaceuticals

Beyond the preview

Go deeper on Tamarisk Technologies Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tamarisk Technologies Group.

Explore the full profile